Biotech is a capital-constrained industry where scientific promise is never enough, and the conversation with Sara Ahmed makes that reality concrete. She explains how drug development actually works from the business side, why most assets fail after millions are spent, and what investors and operators should ask before committing to a platform or disease area. The episode also breaks down the strategic tradeoffs between DNA therapy and RNA editing, and why enterprise-level judgment matters as much as scientific talent.
What You’ll Learn
- How biotech companies move from scientific hypothesis to lead identification, optimization, and clinical trials
- Why the majority of drug candidates fail, even after promising results in lab and animal studies
- Where the money actually goes in drug development, from CROs and site management to manufacturing and R&D
- Why gene therapy, DNA editing, and RNA editing have very different economics, risk profiles, and reimbursement dynamics
- How biotech investors can assess founders, milestones, runway, and market fit before backing a company
Key Discussion Topics
- Sara’s path from hospitals and private practice to CRO work and biotech program leadership
- The structure of the drug development value chain and the difference between big pharma and biotech
- Clinical trial phases, patient enrollment, statistical significance, and why phase 3 is so costly
- The economics of venture-backed biotech, capital efficiency, and why runway is so unforgiving
- DNA therapies versus RNA therapies, including durability, safety, recurrence, and patient access
- Why ultra-rare disease therapies can reach multimillion-dollar price points
- AI as a force multiplier for discovery, knowledge sharing, and reducing duplicated R&D effort
- What scientists can learn from business leaders, and what business leaders can learn from scientists
- The importance of understanding the customer, market, and commercial path before pursuing a biotech idea
Guest Background
Name: Sara Ahmed
Bio: Sara Ahmed is an executive in drug development and biotech program management, with experience spanning clinical operations, corporate strategy, and portfolio planning. Her career has taken her from hospitals and contract research organizations into biotech leadership roles, including program development for RNA editing therapies and earlier-stage gene therapy programs. She brings a practical, enterprise-level view of how science, capital, and execution intersect in one of the most demanding industries in business.
Follow Sara on LinkedIn: LinkedIn
Get engaged
Subscribe to the channel for more conversations that sharpen how you think.
Follow us on social media: Social media
About Business Unbound
Every week, your host, Florian Haufe, dives deep into conversations with visionary global leaders to bring you insights, inspiration, and the real stories behind success.
#BusinessUnbound #Podcast #biotech #drugdevelopment #clinicaltrials #genetherapy #RNAediting
